Tufts Survey Paints Optimistic Outlook for Personalized Rx in Drug Development

A survey by the Tufts Center for the Study of Drug Development reveals that genomically targeted strategies and companion diagnostics are steadily gaining prominence among pharmaceutical companies' pipelines.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.